2013
The STICH Trial (Surgical Treatment for Ischemic Heart Failure) Mode-of-Death Results
Carson P, Wertheimer J, Miller A, O'Connor CM, Pina IL, Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, Velazquez EJ, Investigators S. The STICH Trial (Surgical Treatment for Ischemic Heart Failure) Mode-of-Death Results. JACC Heart Failure 2013, 1: 400-408. PMID: 24621972, PMCID: PMC3829618, DOI: 10.1016/j.jchf.2013.04.012.Peer-Reviewed Original ResearchConceptsMode of deathIschemic cardiomyopathy patientsMedical therapySTICH trialMyocardial infarction deathsCABG therapyCardiomyopathy patientsSudden deathProspective clinical trial dataAddition of CABGStrategy of CABGCoronary artery bypassReduced ejection fractionClinical events committeeClinical trial dataPre-specified definitionsCABG patientsArtery bypassCardiovascular deathNoncardiovascular deathEjection fractionHeart failureEvents committeeProtective effectCABG
2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk